Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling

Osteosarcoma is the most common primary malignant bone tumor, and there are few ideal clinically available drugs. The bromodomain and extraterminal domain (BET) protein is an emerging target for aggressive cancer, but therapies targeting the BET in osteosarcoma have been unsuccessful in clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yafei, Wang, Gangyang, Mu, Haoran, Ma, Xiaojun, Wang, Zhuoying, Lv, Yu, Zhang, Tao, Xu, Jing, Wang, Jinzeng, Li, Yunqi, Han, Jing, Yang, Mengkai, Wang, Zongyi, Zeng, Ke, Jin, Xinmeng, Xue, Song, Yin, Mingzhu, Sun, Wei, Hua, Yingqi, Cai, Zhengdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219214/
https://www.ncbi.nlm.nih.gov/pubmed/34168981
http://dx.doi.org/10.3389/fonc.2021.642134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219214/
https://www.ncbi.nlm.nih.gov/pubmed/34168981
http://dx.doi.org/10.3389/fonc.2021.642134

Ejemplares similares